argenx's $2.2B Forte Tender Offer Clears HSR Antitrust Review
ARGX sits 56% above its 52-week low of $650.01.
Summary
argenx's tender offer for Forte Biosciences cleared U.S. antitrust review, with the HSR waiting period expiring on August 18, 2026.
Key Events · M&A and Partnerships · ARGX
-
HSR Clearance Obtained
The HSR waiting period expired at 11:59 p.m. ET on August 18, 2026, satisfying the HSR Clearance Condition for the tender offer.
-
Tender Offer Terms Unchanged
The offer remains $77.00 per share in cash, net to seller, for all outstanding shares of Forte Biosciences.
-
Remaining Conditions
The offer continues to be subject to other conditions set forth in the Offer to Purchase, including the tender of a majority of shares.
-
Timeline
The tender offer was launched on August 6, 2026; this amendment confirms antitrust clearance as of August 18, 2026.
Analysis · ARGX · Life Sciences
The HSR waiting period expired on August 18, 2026, satisfying a key condition to argenx's $77.00 per share all-cash tender offer for Forte Biosciences. This removes a regulatory hurdle and moves the acquisition closer to completion, though the offer remains subject to other conditions.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARGX was trading at $1,015.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63B. The 52-week trading range was $650.01 to $1,009.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.